Incyte analyst coverage
WebJan 31, 2024 · Analyst Price Forecast Suggests 6.47% Upside As of January 31, 2024, the average one-year price target for Incyte is $89.06. The forecasts range from a low of $63.63 to a high of $129.15. WebApr 13, 2024 · Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. About the company. INCY fundamental analysis. Snowflake Score. …
Incyte analyst coverage
Did you know?
WebBased on 13 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $87.46 with a high forecast of $113.00 and a low forecast of $61.00 . The average price target represents a … WebMar 22, 2024 · Incyte (INCY) Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte yesterday and set a price target of $76.00. The company’s shares closed last Tuesday at $73.49.
WebDec 29, 2024 · Incyte (NASDAQ:INCY) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EPS growth estimates are ... WebApr 9, 2024 · Incyte Co. (NASDAQ:INCY) Receives $86.23 Average PT from Analysts Posted by ABMN Staff on Apr 9th, 2024 Shares of Incyte Co. ( NASDAQ:INCY – Get Rating) have been given an average rating of “Hold” by the eighteen brokerages that are presently covering the company, Marketbeat.com reports.
WebApr 13, 2024 · A high-stakes race among cancer immunotherapy drug developers has hit a roadblock. Merck & Co. and Incyte say a late-stage study combining Merck’s checkpoint inhibitor Keytruda with Incyte’s ... WebFeb 9, 2024 · These 4 analysts have an average price target of $74.25 versus the current price of Incyte at $68.65, implying upside. Below is a summary of how these 4 analysts rated Incyte over the past 3 months.
WebJan 9, 2024 · JP MORGAN HEALTHCARE CONFERENCE JANUARY 9, 2024. Forward-looking statements. Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: expectations regarding 2024 newsflow items; the …
WebJan 18, 2024 · Within the last quarter, Incyte (NASDAQ:INCY) has observed the following analyst ratings: cintho dracenaWebNov 8, 2024 · We would highlight that Incyte's revenue growth is expected to slow, with forecast 16% increase next year well below the historical 23%p.a. growth over the last five years. cinthol blackWebApr 12, 2024 · For the last few months, analysts have been revising downwards their earnings forecast. Over the past twelve months, analysts' consensus has been significantly revised downwards. Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity. diall ae0295 rechargeable led lightWebMar 28, 2024 · According to 13 analyst offering 12-month price targets in the last 3 months, Incyte has an average price target of $94.23 with a high of $113.00 and a low of $60.00. cintho caneWebMay 7, 2024 · Taking into account the latest results, the consensus forecast from Incyte's 20 analysts is for revenues of US$2.44b in 2024, which would reflect a solid 9.3% improvement in sales compared to... cinthol black soapWebBiopharmaceutical Company Solutions for Unmet Medical Needs Incyte.com Our Company What We Do Scientific excellence driven by the need for innovative solutions for patients. Our Passion for Innovation Culture & Careers Passionate individuals bring our ideas to life and help to solve the toughest challenges. Our Awesome Team cinthol bathing soapWebAnalyst Recommendations The current consensus among 21 polled investment analysts is to Hold stock in Incyte Corp. This rating has held steady since April, when it was downgraded from a Buy rating. diall aquastop 5mm extruded polystyrene xps